A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase 2
358
about 2.9 years
18–66
13 sites in AL, CA, FL +9
Why this study is shown
What this study is about
This trial is testing different drug combinations after a stem cell transplant to prevent graft-versus-host disease (GVHD). It involves comparing new drug combinations to standard treatments, and also assessing the safety of each combination. Participants will receive regular check-ups, take surveys about their well-being, and provide blood and stool samples.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Permitted Concomitant Therapy
- 2.Participate in Prohibited Concomitant Therapy
- 3.Receive Supportive Care: Intravenous immune globulin (IVIG)
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, immunosuppressant (Calcineurin inhibitor; suppresses T-cell activation (reduces IL-2))
injection (Injection), oral (Oral Capsule), oral (Oral Tablet), oral
Primary: Graft-versus-host disease-free, relapse-free survival (GRFS)
Secondary: Graft-versus-host disease-free survival (GFS), Incidence of cytokine release syndrome (CRS), Non-relapse mortality (NRM), Overall survival (OS), Progression-free survival (PFS)
Oncology